Quarterly report pursuant to Section 13 or 15(d)

Other Intangible Assets (Tables)

v3.19.1
Other Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets Carrying Value

The net carrying value of the identifiable intangible assets as of March 31, 2019 and December 31, 2018 are as follows:

 

          As of
March 31, 2019 		    As of
December 31, 2018 		 
          (unaudited)        
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
Diagnostic assets:                        
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       18,351       18,351  
Total           $ 43,011     $ 43,011  
Diagnostic lab:                        
CLIA Lab     2.3     $ 609     $ 609  
                         
Accumulated Amortization           $ (14,580 )   $ (10,515 )
                         
Net Carrying Value           $ 29,040     $ 33,105  
Schedule of Future Estimated Amortization Expense

Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

 

2019     2020     2021     2022     2023  
$ 3,252     $ 4,272     $ 4,908     $ 2,987     $ 2,987